The role of MAP-9 and TIMP-1 in nasal polyp formation

Swiss Medical Weekly

Volumn 138, Issue 45-46, 2008, Pages 684-688

  Kahveci, Orhan Kemal ^a,b   Derekoy, Fevzi Sefa ^a   Yilmaz, Mustafa Deniz ^a   Serteser, Mustafa ^a   Altuntas, Ali ^a  

^a AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b KBB AD   (Turkey)

Author keywords

Matrix metalloproteinases; MMP 9; Nasal polyp; Nasal polyp physiopathogenesis; Polyp etiopathogenesis; Polyp formation; TIMP 1

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; ARTICLE; CELL POPULATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NOSE POLYP; NOSE SURGERY; PATHOPHYSIOLOGY; AGED; BIOPSY; COMPARATIVE STUDY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STATISTICAL ANALYSIS; TURBINATE;

ADOLESCENT; ADULT; AGED; BIOPSY; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NASAL POLYPS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TURBINATES;

EID: 56749153080     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kennedy DW, Bolger WE, Zinreich SJ. Diseases of the Sinuses: Current Therapy and Management. Philadelphia, PA: B.C. Decker; 2001.
2. Drake-Lee A. The pathogenesis of nasal polyps. In Settipane GA, Lund VJ, Bernstein JM, Tos M eds. Nasal Polyps: Epidemiology, Pathogenesis and treatment. Rhode Islands, OceanSide Publications Inc. 1997:57-64.
3. Larsen PL, Tos M, Kuijpers W, van der Beek JMH. The early stages of polyp formation. Laryngoscope. 1992;102:670-7.
4. Morinaka S, Nakamura H. Inflammatory cells in nasal mucosa and nasal polyps. Auris Nasus Larynx. 2000;27;59-64.
5. Pawankar R. Nasal polyposis: an update. Curr Opin Allergy Clin Immunol. 2003;3:1-6.
6. Hoffman HM, Wasserman SIChemical mediators in polyps. In Settipane GA, Lund VJ, Bernstein JM, Tos M eds. Nasal Polyps: Epidemiology, Pathogenesis and treatment. Rhode Islands OceanSide Publications Inc. 1997:41-8.
7. Nagase H, Woessner JF Jr. Matrix metalloproteinases.J Biol Chem. 1999;274:21491-4.
8. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc. 2002;92: 12-8.
9. Lemjabbar H, Gusset P, Lamblin C, Tillie I, Hartmann D, Wallaert B, Tonnel AB, Lafuma C. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med. 1999;159:1298-307.
10. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax.. 2007;62:706-13.
11. Pawankar R, Watanabe S, Nonaka M, Ozu C, Aida M, Yagi T., Differential expression of matrix metalloproteinase 2 and 9 in the allergic nasal mucosa and nasal polyps. J Allergy Clin Immunol. 2004;Supplement;113:1229 (abstract).
12. Lechapt-Zalcman E, Coste A, d'Ortho MP, Frisdal E, Harf A, Lafuma C, Escudier E. Increased expression of matrix metalloproteinase-9 in nasal polyps. J Pathol. 2001;193(2):233-41.
13. Watelet JB, Bachert C, Claeys C, Van Cauwenberge P. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs nasal polyposis. Allergy. 2004;59:54-60.
14. Chen YS, Langhammer T, Westhofen M, Lorenzen J. Relationship between matrix metalloproteinases MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinases-1 and IL-5, IL-8 in nasal polyps. Allergy. 2007;62:66-72.
15. Can IH, Ceylan K, Caydere M, Samim EE, Ustun H, Karasoy DS. The expression of MMP-2, MMP-7, MMP-9, and TIMP-1 in chronic rhinosinusitis and nasal polyposis. Otolaryngol Head Neck Surg. 2008;139:211-5.
16. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Critical reviews in oncology/hematology. 2004; 49:187-98.
17. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg. 2000;105:638-47.
18. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324-33.
19. Lee YM, Kim SS, Kim HA, Suh YJ, Lee SK, Nahm DH, Park HS. Eosinophil inflammation of nasal polyp tissue: relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1. J Korean Med Sci. 2003;18:97-102.
20. Tos M. Early stages of polyp formation. In Settipane GA, Lund VJ, Bernstein JM, Tos M eds. Nasal Polyps: Epidemiology, Pathogenesis and treatment. Rhode Islands, OceanSide Publications Inc. 1997:65-72.
21. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-9.
22. Olsen CE, Liguori AE, Zong Y, Lantz RC, Burgess JL, Boitano S. Arsenic upregulates MMP-9 and inhibits wound repair in human airway epithelial cells.Am J Physiol Lung Cell Mol Physiol. 2008;295:293-302.
23. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res. 1999;19:1589-92.
24. Toi M, Ishigaki S, Tominaga T. Metalloproteinases and tissue inhibitors of metalloproteinases.Breast Cancer Res Treat. 1998; 52:113-24.
25. Watelet JB, Clays C, Cauwanberge PV, Bachert C. Matrix metalloproteinases in chronic sinus diseases. Int Cong Ser. 2003; 1240:483-5.